Dubai: The landscape of single-dose vaccines against COVID-19 just got more interesting. On Sunday, US health authorities approved the Janssen vaccine as a single-shot against COVID, with 78% efficacy. This is seen as a “game changer” in the global counter-coronavirus drive.
Data from the clinical trials and massive vaccination rollouts lead some experts to make a case for single shots from Pfizer and Moderna vaccines, too. The latter two are messenger RNA vaccines currently being rolled out in North America, Europe and the Middle East as a double dose.
With millions of doses per day being administered, there’s a decent amount of information for data scientists to crunch. Some experts argue this delayed or “fractional” dosing, could help the world achieve herd immunity sooner. Other scientists oppose the strategy. Here’s the lowdown on single-dose COVID shots:
Arcturus Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Positive Clinical Updates
yahoo.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from yahoo.com Daily Mail and Mail on Sunday newspapers.
Would a single-shot COVID-19 vaccine accelerate fight against coronavirus?
gulfnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from gulfnews.com Daily Mail and Mail on Sunday newspapers.
(Bloomberg) Vaccine developers slumped as Johnson & Johnson appeared to be nearing regulatory approval for its shot in the U.S., which would be the third available in the country.The biotechnology companies racing to come up with new shots for Covid-19 were mostly lower after a bumpy week. Pfizer Inc. and its German vaccine partner, BioNTech SE, slid on Friday. The duo were down less than 1% each, despite positive real world-results of their vaccine in Israel, as investors continue to assess how long the pandemic could persist and how big the future vaccine market may be.For Johnson & Johnson, the largest drugmaker in the country by market value, the prospect of its vaccination winning regulatory approval wasn’t enough to stop shares from tumbling 2.4%. A panel of outside experts is weighing the company’s one-shot regimen on Friday as the Food and Drug Administration considers a speedy authorization.Analysts are expecting the FDA to clear J&J’s sho
Axsome Therapeutics Inc (NASDAQ: AXSM) (before the market open)
Amicus Therapeutics, Inc. (NASDAQ: FOLD) (before the market open)
Biohaven Pharmaceutical Holding Co Ltd (NYSE: BHVN) (before the market open)
Athenex Inc (NASDAQ: ATNX) (before the market open)
Agile Therapeutics Inc (NASDAQ: AGRX) (after the close)
Atara Biotherapeutics Inc (NASDAQ: ATRA) (after the close)
Arcturus Therapeutics Holdings Inc (NASDAQ: ARCT) (after the close)
Adverum Biotechnologies Inc (NASDAQ: ADVM) (after the close)
Omeros Corporation (NASDAQ: OMER) (after the close)
ChemoCentryx Inc (NASDAQ: CCXI) (after the close)
FibroGen Inc (NASDAQ: FGEN) (after the close)
Inovio Pharmaceuticals Inc (NASDAQ: INO) (after the close)
Precigen Inc (NASDAQ: PGEN) (after the close)